Join the Oncology Voice Network. Join for Free
Prepare to LAUNCH: How to Build an MSL Team From Scratch
MSL team building drug launch strategy medical science liaison recruitment field medical team best practices MSL training phases

Prepare to LAUNCH: How to Build an MSL Team From Scratch


Share This Article


Summary

In episode 152, Tom Caravela is joined by John Caskey to delve into the intricacies of assembling the ideal MSL team for a successful drug launch. The discussion covers strategic timing, the importance of leadership, and the sequence of hiring MSLs. Operational requirements such as team size, territory allocation, and KOL support management are explored, alongside the recruiting timeline. The episode highlights key skills and criteria essential for selecting MSLs and emphasizes the need for comprehensive training, detailing how to balance different training phases. The conversation wraps up with a summary of best practices for building an effective field medical team.

Tom Caravela, Managing Partner at The Carolan Group and Host of the MSL Talk Podcast, is interviewed by Jon Kaskey on how to build an MSL team in preparation for a drug launch.
Tom shares….

👉 How early should companies consider hiring MSLs
👉 Who spearheads the process for building out the team
👉 What factors go into determining the number of MSLs per team
👉 How are territories aligned and allocated
👉 What other factors need to be considered for internal medical affairs preparedness

Click for Source
MSL team building, drug launch strategy, medical science liaison recruitment, field medical team best practices, MSL training phases

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Article
Model-Informed Therapeutic Dose Optimization Strategies for Antibody-Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration-Approved Antibody-Drug Conjugates?
OVN Avatar Michael Z. Liao, Dan Lu, Matts Kågedal, Dale Miles, Divya Samineni, Stephanie N. Liu, Chunze Li

Model-Informed Therapeutic Dose Optimization Strategies for Antibody-Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration-Approved Antibody-Drug Conjugates?

Podcast
MSL Career Options: The transition from Field Medical to Medical Director
Partner Avatar MSL Talk: Tom Caravela, Josh Corriveau

MSL Career Options: The transition from Field Medical to Medical Director

Article
Cancer, Clinical Trials, and Canada: Our Contribution to Worldwide Randomized Controlled Trials
OVN Avatar Shubham Sharma, J Connor Wells, Wilma M Hopman, Joseph C Del Paggio, Bishal Gyawali, Nazik Hammad, Annette E Hay, Christopher M Booth

Cancer, Clinical Trials, and Canada: Our Contribution to Worldwide Randomized Controlled Trials

Article
CheckMate-067: Raising the Bar for the Next Decade in Oncology
OVN Avatar Sarah A. Weiss, MD, and Harriet Kluger, MD

CheckMate-067: Raising the Bar for the Next Decade in Oncology

Article
Confounding factors in exposure–response analyses and mitigation strategies for monoclonal antibodies in oncology
OVN Avatar Sonoko Kawakatsu, René Bruno, Matts Kågedal, Chunze Li, Sandhya Girish, Amita Joshi, Benjamin Wu

Confounding factors in exposure–response analyses and mitigation strategies for monoclonal antibodies in oncology

Article
EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for hematological malignancies
OVN Avatar Barbara Kiesewetter , Nathan I Cherny, Nicolas Boissel, Francesco Cerisoli, Urania Dafni, Elisabeth G E de Vries, Paolo Ghia, Nicola Gökbuget, Verónica González-Calle, Brian Huntly, Ulrich Jäger, Nicola Jane Latino, Jean-Yves Douillard, Luca Malcovati, Ma

EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for hematological malignancies

Explore OVN